Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains

Revvity reported Q1 2026 earnings with EPS of $1.06 beating estimates by $0.04 and revenue up 7% year-over-year. Shares rose 0.31% to $101.32 on May 8 on NYSE, while TD Cowen raised its price target to $120.

Revvity shares advanced 0.31% to close at $101.32 on May 8, 2026 on the NYSE, propelled by stronger-than-expected Q1 CY2026 earnings released on May 5, according to MarketBeat as of 05/08/2026. The company posted EPS of $1.06, topping consensus estimates of $1.02 by $0.04, with revenue increasing 7% year-over-year to $711.12 million, per ad-hoc-news as of 05/08/2026. Separately, TD Cowen lifted its price target to $120 on May 7.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life sciences tools and diagnostics
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Discovery & innovation solutions, diagnostics
• Home exchange/listing venue: NYSE (RVTY)
• Trading currency: USD

Revvity: core business model

Revvity provides health science solutions including instruments, consumables, software, and services for life sciences, diagnostics, and biopharma. The company operates through two main segments: Discovery & Innovation and Diagnostics. These focus on drug discovery, development, and clinical diagnostics, serving pharmaceutical, biotech, academic, and healthcare customers globally. Revvity's market cap stood at $11.33 billion as of May 8, 2026, per MarketBeat as of 05/11/2026.

Main revenue and product drivers for Revvity

Revenue growth in Q1 CY2026 reached 7% year-over-year to $711.12 million, driven by demand in life sciences tools and diagnostics amid biopharma R&D investments. Key products include mass spectrometry systems, genetic screening tools, and imaging solutions. The company reported a net margin of 8.26% and return on equity of 8.00% for the quarter ending March 2026, according to MarketBeat data as of May 11, 2026. Year-to-date through May 8, shares gained 4.7% from $96.81.

Industry trends and competitive position

The life sciences tools sector benefits from rising biopharma R&D spending in the US, where Revvity derives significant exposure. Peers include Thermo Fisher and Danaher. Revvity's P/E ratio was 48.48 with a beta of 1.05 as of May 11, 2026, per MarketBeat. Its 50-day moving average stood at $90.30 and 200-day at $96.90, reflecting recent strength.

Why Revvity matters for US investors

Listed on NYSE as RVTY, Revvity offers US investors direct access to the diagnostics and life sciences tools market, critical to the US healthcare economy. With a $1 billion share repurchase authorization from October 27, 2025, per MarketBeat as of 05/08/2026, the company underscores capital return focus amid sector tailwinds.

Conclusion

Revvity's Q1 2026 earnings beat, revenue growth, and TD Cowen price target upgrade signal operational momentum in life sciences. The stock's 4.7% YTD gain and $1 billion buyback program highlight strategic confidence. US investors track its role in biopharma tools amid market volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.